Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 46M | 22.6% |
| Net Income | -43M | 22.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 300M | 13% |
| Total Liabilities | 80M | 9% |
| Total Equity | 220M | 14.4% |
| Shares Outstanding | 61M | 0.3% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -41M | 16.9% |
EPS
Financial Highlights for Pliant Therapeutics in Q2 '25
Operating Expenses for this period were 46M, showing a -22.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -43M, showing a 22.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
